Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 2433Neoplasms 1842Carcinoma, Non-Small-Cell Lung 1609Prostatic Neoplasms 1312Colorectal Neoplasms 1144Lung Neoplasms 991Neoplasm Metastasis 835Multiple Myeloma 800Leukemia, Myeloid, Acute 778Ovarian Neoplasms 685Pancreatic Neoplasms 671Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Carcinoma, Hepatocellular 570Recurrence 568Brain Neoplasms 528Glioblastoma 519Stomach Neoplasms 503Head and Neck Neoplasms 502Triple Negative Breast Neoplasms 473Lymphoma 461Uterine Cervical Neoplasms 457Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 421Lymphoma, Non-Hodgkin 390Endometrial Neoplasms 386Sarcoma 369Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 356Lymphoma, Follicular 356

Interventions

Cisplatin 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal Squamous Carcinoma × 1 year × Clear all
NCT07490002 2026-03-24

Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC

Changhai Hospital

Phase 2 Not yet recruiting
33 enrolled
Gastrointestinal

Esophageal Squamous Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡